Skip to content

Category: 1

Healing the gut after cancer therapy: Immune cells turn damage into repair

27.11.2025

Regulatory T cells (Tregs), a specialized type of immune cells, are usually seen as “peacekeepers” that prevent excessive immune attacks. Surprisingly, a new study published in “Signal Transduction and Targeted Therapy” shows that Tregs utilize inflammatory signals to start repair processes following cancer therapy. The research conducted by the LIT Cooperation Group “Innate Immune Sensing in Cancer and Transplantation” in cooperation with researchers from the Department of Radiation Oncology at the Technical University of Munich (TUM) uncovers how the body`s own immune system can be harnessed to repair the intestinal lining and improve survival.

For more transparency in the literature: Prof. Carmen Gerlach contributed to the “Guidelines for T cell nomenclature”

25.11.2025

A consensus statement published in “Nature Reviews Immunology” provides consensus definitions for common T cell subsets, and additionally proposes a modular nomenclature for defining T cell states – both to facilitate clearer communication of findings and concepts to researchers, students and clinicians. Prof. Carmen Gerlach, Head of Research Division “Tailored T-Cell Diversity” at the LIT, is one of the authors.

Strategic Collaboration for Advancing Immunotherapies in Rheumatic Diseases

21.11.2025

The executive boards of the Leibniz Institute for Immunotherapy (LIT) and the German Rheumatology Research Center (DRFZ) in Berlin have signed a “Memorandum of Understanding”. The two Scientific Directors, Prof. Dr. Philipp Beckhove and Prof. Dr. Eicke Latz, aim for strategic cooperation in the areas of research, training, scientific infrastructure, and data exchange, including the establishment of a joint working group.

New GMP/GCP Seminar Series at the LIT

10.11.2025

For about six months since March, around 50 postdocs, PhDs and master students at the LIT went through an entire curriculum program mediating knowledge about Good Manufacturing Practice (GMP) and Good Clinical Practice (GCP).

Head of Translation Group “T-Cell Fitness” Roland Schelker is now Associate Professor: Interview in Immunopaedia traces his path to the LIT

27.10.2025

“Stay curious.” That is only one of the practical pieces of advice Roland Schelker gives in his interview for early-career researchers. The statements are published on Immunopaedia.org, a non-profit platform providing free immunology education. Schelker, Head of the Translation Group “T-Cell Fitness”, recently became an Associate Professor at the University of Regensburg.

Canada’s 2025 Taylor Prize awarded to LIT Scientific Advisory Board member Carl H. June for his pioneering work in CAR T-cell therapy

20.10.2025

The 2025 Taylor Prize is dedicated to the transformative potential of cell-based immunotherapy. As Western University, London, Ontario, Canada, in its award announcement says, Prof. Carl H. June’s work is “advancing our understanding of immune-based treatments and reshaping the possibilities of human health”. The Taylor Prize is one of Canada’s most prestigious medical research prizes and includes a cash award of 50,000 U.S. dollars.